Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436475 | 0.81 | TNK2 (0.37) | ABL1SRCTNK2RETKDR | |
| SCHEMBL18099733 | 0.81 | ABL1 (0.53) | ABL1SRCTNK2RETKDR | |
| SCHEMBL18956083 | 0.78 | IDO1 (0.34) | — | |
| SCHEMBL3535319 | 0.78 | — | — | |
| SCHEMBL19652459 | 0.74 | TNK2 (0.37) | TNK2 | |
| SCHEMBL20254980 | 0.73 | TP53 (0.34) | — | |
| SCHEMBL31391125 | 0.72 | ABL1 (0.30) | ABL1 | |
| SCHEMBL18849863 | 0.71 | KMT2A (0.35) | ABL1SRCTNK2RETKDR | |
| SCHEMBL31330569 | 0.71 | LMNA (0.35) | — | |
| SCHEMBL31330573 | 0.71 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380375-A1 | SUBSTITUTED AROMATIC FUSED RING DERIVATIVE AND COMPOSITION COMPRISING SAME, AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-12-01 | — | — | US | disclosed |
| EP-4043465-A1 | SUBSTITUTED AROMATIC FUSED RING DERIVATIVE AND COMPOSITION COMPRISING SAME, AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| CN-114621233-A | Substituted aromatic condensed ring derivative and its composition and use | 深圳市塔吉瑞生物医药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-112552302-B | Substituted aromatic fused ring derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021057877-A1 | SUBSTITUTED AROMATIC FUSED RING DERIVATIVE AND COMPOSITION COMPRISING SAME, AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112552302-A | Substituted aromatic fused ring derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | ABL1 16/4885SRC 3/4885TNK2 43/4885 |
| US-20220380375-A1 | SUBSTITUTED AROMATIC FUSED RING DERIVATIVE AND COMPOSITION COMPRISING SAME, AND USE THEREOF | SRC, TH, RET | ABL1 10/4885SRC 1/4885TNK2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.